Impact of Patient Navigation on Time to Treatment Among Patients With GI Cancers at Rwanda Military Referral and Teaching Hospital.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
151 patients, with 85 patients in the post-PNP group, were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Despite the important findings, some limitations remain; hence, further studies are recommended to provide more comprehensive evidence. Integrating PNP into national cancer control strategies is essential to strengthen care coordination and ensure timely access to cancer treatment in low-resource settings like Rwanda.
[PURPOSE] To evaluate the impact of a patient navigation program (PNP) on treatment delays among patients with GI cancers at the Rwanda Military Referral and Teaching Hospital (RMRTH).
APA
Kwizera V, Aihnoa CC, et al. (2026). Impact of Patient Navigation on Time to Treatment Among Patients With GI Cancers at Rwanda Military Referral and Teaching Hospital.. JCO global oncology, 12(3), e2500339. https://doi.org/10.1200/GO-25-00339
MLA
Kwizera V, et al.. "Impact of Patient Navigation on Time to Treatment Among Patients With GI Cancers at Rwanda Military Referral and Teaching Hospital.." JCO global oncology, vol. 12, no. 3, 2026, pp. e2500339.
PMID
41791010 ↗
Abstract 한글 요약
[PURPOSE] To evaluate the impact of a patient navigation program (PNP) on treatment delays among patients with GI cancers at the Rwanda Military Referral and Teaching Hospital (RMRTH).
[METHODS] PNP is a personalized support model implemented at RMRTH on April 1, 2023, to guide patients with a cancer diagnosis through the health care system. We used a quasi-experimental study design and included all patients diagnosed and treated for esophageal, gastric, or colorectal cancer in pre- and postimplementation of PNP at RMRTH. The outcomes of interest were measured in days: treatment interval from pathology report to treatment initiation. Data were abstracted from patients' medical records and analyzed using STATA version 19. The Wilcoxon rank-sum test was performed. Treatment intervals were used in the time series analysis, and the Dickey-Fuller Test was used to test stationarity.
[RESULTS] A total of 151 patients, with 85 patients in the post-PNP group, were included. The mean age (years) at diagnosis was similar (59.4 ± 13.5 years in the pre-PNP and 59 ± 14.18 years in the post-PNP group). Most patients (80.0% pre-PNP group and 80.9% post-PNP group) presented with stage III/IV. Neoadjuvant chemotherapy was the most common initial treatment (48.5% pre-PNP and 54.1% post-PNP). The median treatment interval decreased from 53.5 days (IQR, 26-129) in the pre-PNP group to 32 days (IQR, 14-63) in the post-PNP group ( < .001). The reductions in treatment delays were significant over time following the implementation of the PNP ( = .004).
[CONCLUSION] PNP reduced treatment delays among patients with GI cancers at RMRTH. Despite the important findings, some limitations remain; hence, further studies are recommended to provide more comprehensive evidence. Integrating PNP into national cancer control strategies is essential to strengthen care coordination and ensure timely access to cancer treatment in low-resource settings like Rwanda.
[METHODS] PNP is a personalized support model implemented at RMRTH on April 1, 2023, to guide patients with a cancer diagnosis through the health care system. We used a quasi-experimental study design and included all patients diagnosed and treated for esophageal, gastric, or colorectal cancer in pre- and postimplementation of PNP at RMRTH. The outcomes of interest were measured in days: treatment interval from pathology report to treatment initiation. Data were abstracted from patients' medical records and analyzed using STATA version 19. The Wilcoxon rank-sum test was performed. Treatment intervals were used in the time series analysis, and the Dickey-Fuller Test was used to test stationarity.
[RESULTS] A total of 151 patients, with 85 patients in the post-PNP group, were included. The mean age (years) at diagnosis was similar (59.4 ± 13.5 years in the pre-PNP and 59 ± 14.18 years in the post-PNP group). Most patients (80.0% pre-PNP group and 80.9% post-PNP group) presented with stage III/IV. Neoadjuvant chemotherapy was the most common initial treatment (48.5% pre-PNP and 54.1% post-PNP). The median treatment interval decreased from 53.5 days (IQR, 26-129) in the pre-PNP group to 32 days (IQR, 14-63) in the post-PNP group ( < .001). The reductions in treatment delays were significant over time following the implementation of the PNP ( = .004).
[CONCLUSION] PNP reduced treatment delays among patients with GI cancers at RMRTH. Despite the important findings, some limitations remain; hence, further studies are recommended to provide more comprehensive evidence. Integrating PNP into national cancer control strategies is essential to strengthen care coordination and ensure timely access to cancer treatment in low-resource settings like Rwanda.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.